{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:56:29Z","timestamp":1789059389589,"version":"build-2803163510"},"reference-count":23,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trofinetide (TROF) became the first approved pharmacologic treatment for Rett syndrome (RTT) in the United States in March 2023; however, real-world evidence comparing TROF-treated and untreated individuals is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the baseline demographic and clinical profiles of those treated with TROF vs untreated in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used linked IQVIA Anonymized Patient Level Database medical claims and a specialty pharmacy database. Individuals with \u22651 medical claim for RTT between 01\/01\/2021 and 09\/30\/2024 (study period) were identified. Treated individuals had \u22651 TROF prescription during 04\/01\/2023 to 09\/30\/2023 (identification period), with first prescription set as index; untreated individuals had no TROF prescription. A risk-set sampling approach was used to assign proxy index dates to untreated individuals to improve comparability and reduce immortal time bias. Individuals with cerebrovascular disease or brain trauma before RTT diagnosis and those without 12 months pre-and post-index enrollment were excluded. Baseline characteristics were assessed during the 12 months pre-index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 8047 individuals with RTT identified, 2950 met eligibility criteria; 766 (26.0%) were treated with TROF and 2184 (74.0%) remained untreated. Treated individuals were younger at index (15.4 vs 23.5 years), and a greater proportion were pediatric (\u226417 years; 66.6% vs 38.3%). Females predominated in both groups, while males represented a smaller proportion of the treated (4.6% vs 10.8%). Treated individuals more frequently had documented nonspecific developmental delay (31.3% vs 21.6%), autism spectrum disorder (19.1% vs 15.7%), and core RTT-related neurodevelopmental features such as loss of acquired communication skills (23.8% vs 12.9%) and loss of acquired motor skills (11.1% vs 4.9%). Child neurology was the most common prescriber specialty in both groups and was more frequent among treated individuals (50.3% vs 26.8%). Overall comorbidity burden was broadly similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusion\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world analysis, only one-quarter of eligible individuals with RTT initiated TROF during the early post-approval period. TROF uptake appeared concentrated in younger, specialist-managed individuals with more clearly documented RTT-related features, while three-quarters remained untreated. These findings highlight the need to better understand treatment pathways and barriers to initiation in males and adults in routine RTT care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.162589","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:11:22Z","timestamp":1781208682000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States"],"prefix":"10.36469","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-1234","authenticated-orcid":false,"given":"Nazia","family":"Rashid","sequence":"first","affiliation":[{"name":"Acadia Pharmaceuticals, San Diego, California","department":["Medical Affairs"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1576-0977","authenticated-orcid":false,"given":"Vinod K.","family":"Yakkala","sequence":"additional","affiliation":[{"name":"Anlitiks Inc, Windermere, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-864X","authenticated-orcid":false,"given":"Safiuddin S.","family":"Syed","sequence":"additional","affiliation":[{"name":"Anlitiks Inc, Windermere, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-0822","authenticated-orcid":true,"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"Anlitiks Inc, Windermere, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s13023-024-03313-8","article-title":"Burden of illness in Rett syndrome: initial evaluation of a disorder-specific caregiver survey","volume":"19","author":"W. E. Kaufmann","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s11689-024-09557-6","article-title":"Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database","volume":"16","author":"D. May","year":"2024","journal-title":"J Neurodev Disord"},{"key":"ref3","article-title":"Acadia Pharmaceuticals announces U.S. FDA approval of DAYBUE\u2122 (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older","author":"Acadia Pharmaceuticals","year":"2023"},{"issue":"5","key":"ref4","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1097\/MS9.0000000000001896","article-title":"Trofinetide receives FDA approval as first drug for Rett syndrome","volume":"86","author":"Z. U. N. Mughal","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"J. L. Neul","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"ref6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.medj.2024.05.015","article-title":"Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study","volume":"5","author":"A.K. Percy","year":"2024","journal-title":"Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.07.013","article-title":"Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study","author":"A.K. Percy","year":"2024","journal-title":"Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.16482","article-title":"Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: the LOTUS study","author":"K. L. Cosand","year":"2025","journal-title":"Dev Med Child Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cns3.70062","article-title":"Expert consensus on real-world use of trofinetide for Rett syndrome using a modified Delphi method","author":"L. Prange","year":"2026","journal-title":"Ann Child Neurol Soc"},{"issue":"9","key":"ref10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10654-022-00898-x","article-title":"Stress-related disorders and subsequent cancer risk and mortality: a population-based and sibling-controlled cohort study in Sweden","volume":"37","author":"F. Tian","year":"2022","journal-title":"Eur J Epidemiol"},{"issue":"37","key":"ref11","first-page":"723","article-title":"Uber ein eigenartiges hirnatrophisches Syndrom bei Hyperammon\u00e4mie im Kindersalter. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]","volume":"116","author":"A. Rett","year":"1966","journal-title":"Wien Med Wochenschr"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-016-0202-x","article-title":"Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study","volume":"16","author":"C. F. Lin","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"ref13","doi-asserted-by":"publisher","first-page":"100608","DOI":"10.1016\/j.medj.2025.100608","article-title":"Results from the phase 2\/3 DAFFODIL study of trofinetide in girls aged 2\u20134 years with Rett syndrome","volume":"6","author":"A.K. Percy","year":"2025","journal-title":"Med"},{"issue":"6","key":"ref14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.pediatrneurol.2015.01.014","article-title":"Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis","volume":"52","author":"D. C. Tarquinio","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12883-023-03181-y","article-title":"Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study","volume":"23","author":"D. May","year":"2023","journal-title":"BMC Neurol"},{"issue":"4","key":"ref16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ana.410140412","article-title":"A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases","volume":"14","author":"B. Hagberg","year":"1983","journal-title":"Ann Neurol"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"R. E. Amir","year":"1999","journal-title":"Nat Genet"},{"issue":"6","key":"ref18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"J. L. Neul","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","article-title":"Global prevalence of Rett syndrome: systematic review and meta-analysis","volume":"12","author":"U. Petriti","year":"2023","journal-title":"Syst Rev"},{"issue":"2","key":"ref20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1021\/acschemneuro.7b00346","article-title":"Rett syndrome: a genetic update and clinical review focusing on comorbidities","volume":"9","author":"W. A. Gold","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"ref21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s0387-7604(87)80062-1","article-title":"Rett syndrome: epidemiology and nosology--progress in knowledge 1986--a conference communication","volume":"9","author":"B. Hagberg","year":"1987","journal-title":"Brain Dev"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"e000717","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"C. Fu","year":"2020","journal-title":"BMJ Paediatr Open"},{"issue":"10","key":"ref23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/BRS.0000000000001399","article-title":"The natural history of scoliosis in females with Rett syndrome","volume":"41","author":"J. Downs","year":"2016","journal-title":"Spine"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/162589-real-world-treatment-landscape-of-individuals-with-rett-syndrome-treated-and-untreated-with-trofinetide-in-the-united-states","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:11:23Z","timestamp":1781208683000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/162589-real-world-treatment-landscape-of-individuals-with-rett-syndrome-treated-and-untreated-with-trofinetide-in-the-united-states"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.162589","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}